Biogen, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:BIIB
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 99 out of 909
Universe
Global Universe 5104 out of 16009
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Horizon Therapeutics Plc |
17.2
Low
|
52 out of 909 |
Illumina, Inc. |
19
Low
|
77 out of 909 |
Biogen, Inc. |
20.5
Medium
|
99 out of 909 |
argenx SE |
25.2
Medium
|
226 out of 909 |
Celltrion, Inc. |
30.1
High
|
536 out of 909 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Biogen, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Biogen, Inc.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Top Material ESG Issues for Biogen, Inc.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
![blurred material ESG issues](/ResourcePackages/Sustainalytics/assets/img/company-rating/mei-blur.png)
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Biogen, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level
![blurred controversy level](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-level-blur.jpg)
Contributing Events
![blurred controversy events](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-blur.jpg)
Highest Controversy Events Locations
![world map blurred](/ResourcePackages/Sustainalytics/assets/img/company-rating/cr-events-map-blur.jpg)